Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Last $10.14 USD
Change Today -0.21 / -2.03%
Volume 267.7K
OMER On Other Exchanges
As of 5:20 PM 02/9/16 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

201 Elliott Avenue West

Seattle, WA 98119

United States

Phone: 206-676-5000

Fax: 206-676-5005

Omeros Corporation, a biopharmaceutical company, discovers, develops and commercializes small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. Omidria (phenylephrine and ketorolac injection) 1%/0.3% Omidria was approved by the U.S. Food and Drug Administration (FDA) in 2014 for use during cataract surgery or intraocular lens replacement surgery to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. Omidria is a proprietary drug product containing two active pharmaceutical ingredients (APIs): ketorolac, an anti-inflammatory agent, and phenylephrine, a mydriatic, or pupil dilating, agent. In the European Union (EU), the company submitted a Marketing Authorisation Application to the European Medicines Agency (EMA) in 2013 seeking the authorization to permit it to market and sell Omidria in the EU for use in patients undergoing cataract and intraocular lens replacement surgery. PharmacoSurgery Platform The company generates from its PharmacoSurgery platform proprietary products, such as Omidria, and product candidates that are combinations of therapeutic agents designed to act simultaneously at multiple discrete targets to block preemptively the molecular-signaling and biochemical cascade caused by surgical trauma and to provide clinical benefits both during and after surgery. Clinical Programs MASP Program - OMS721 The company is developing Mannan-binding lectin-associated serine protease-2 (MASP-2) antibodies and it expects that the intended therapeutic effect can be achieved with subcutaneous and other systemic routes of administration. OMS721 is the company’s primary human monoclonal antibody targeting MASP-2. OMS721 has received Orphan Drug designation for the prevention (inhibition) of complement-mediated thrombotic microangiopathies (TMAs). In April 2014, the company concluded a Phase 1 trial in Europe evaluating OMS721. Phosphodiesterase 10 (PDE10) Programs - OMS824 for Schizophrenia and Huntington’s disease PDE10, is an enzyme that is expressed in areas of the brain strongly linked to diseases that affect cognition, including schizophrenia and Huntington’s disease. Cognitive dysfunction occurs early in these diseases and is responsible for substantial disability. The company’s proprietary compound OMS824 inhibits PDE10 and is being developed in clinical programs for the treatment of cognitive disorders, including schizophrenia and Huntington’s disease. OMS824 has received Orphan Drug designation for the treatment of Huntington’s disease and Fast Track designation for the treatment of cognitive impairment in patients with Huntington’s disease. OMS103-Arthroscopy OMS103 is the company’s PharmacoSurgery product candidate being developed for use during arthroscopic procedures, including partial meniscectomy surgery, and was designed to provide a multimodal approach to block preemptively the inflammatory cascade induced by arthroscopy. In 2012, the company completed a multicenter, double-blind, Phase 3 clinical trial comparing OMS103 to vehicle control in 344 patients undergoing arthroscopic partial meniscectomy surgery. Peroxisome Proliferator-Activated Receptor Gamma (PPAR?) Program - OMS405 In its PPAR? program, the company is developing proprietary compositions that include PPAR ? agonists for the treatment and prevention of addiction to substances of abuse, which may include opioids, nicotine and alcohol. OMS201-Urology OMS201 is the company’s PharmacoSurgery product candidate being developed for use during urological procedures, including ureterscopy for removal of ureteral or renal stones. OMS201 is a proprietary combination of an anti-inflammatory API and a smooth muscle relaxant API.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OMER:US $10.14 USD -0.21

OMER Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $24.52 USD +0.46
Diplomat Pharmacy Inc $28.42 USD +1.36
Fagron €4.81 EUR -0.248
Imprimis Pharmaceuticals Inc $4.66 USD +0.062
Ocular Therapeutix Inc $5.54 USD -0.07
View Industry Companies

Industry Analysis


Industry Average

Valuation OMER Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 56.0x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 47.0x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact OMEROS CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at